For the quarter ending 2025-09-30, ANIK made $48,477K in revenue. -$2,513K in net income. Net profit margin of -5.18%.
| Income Statement | 2025-09-30 | 2025-06-30 | 2024-09-30 | 2024-06-30 |
|---|---|---|---|---|
| Foreign currency translation adjustment | -184 | 1,348 | 715 | -101 |
| Cost of product revenue | 12,233 | 13,856 | 37,313 | 14,556 |
| Revenue | 27,817 | 28,219 | 38,753 | 41,921 |
| Gross profit | 15,584 | 14,363 | 1,440 | 27,365 |
| Long lived asset impairment | - | - | 3,101 | - |
| Research & development | 6,946 | 6,313 | 7,244 | 7,398 |
| Selling, general & administrative | 11,871 | 12,230 | 19,112 | 19,806 |
| Total operating expenses | 18,817 | 18,543 | 29,457 | 27,204 |
| Loss from operations | -3,233 | -4,180 | -28,017 | 161 |
| Interest and other income (expense), net | 997 | 214 | 406 | 595 |
| (loss) income before income taxes | -2,236 | -3,966 | -27,611 | 756 |
| Provision for income taxes | 939 | 681 | 2,307 | 844 |
| Loss from continuing operations | -3,175 | -4,647 | - | - |
| Income (loss) from discontinued operations, net of tax | 846 | 677 | - | - |
| Net loss | -2,329 | -3,970 | -29,918 | -88 |
| Comprehensive loss | -2,513 | -2,622 | -29,203 | -189 |
| Basic (in shares) | 14,419,000 | 14,364,000 | 14,768,000 | 14,839,000 |
| Diluted (in shares) | 14,419,000 | 14,517,000 | 14,768,000 | 14,839,000 |
| Us-gaap_earningspersharebasic | -0.16 | -0.28 | -2.03 | -0.01 |
| Us-gaap_earningspersharediluted | -0.16 | -0.28 | -2.03 | -0.01 |
Anika Therapeutics, Inc. (ANIK)
Anika Therapeutics, Inc. (ANIK)